A
Amit M. Oza
Researcher at Princess Margaret Cancer Centre
Publications - 542
Citations - 25057
Amit M. Oza is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 65, co-authored 485 publications receiving 19164 citations. Previous affiliations of Amit M. Oza include University Health Network & Ontario Institute for Cancer Research.
Papers
More filters
Journal ArticleDOI
Evolve: A post PARP inhibitor clinical translational phase II trial of cediranib-olaparib in ovarian cancer—A Princess Margaret Consortium – GCIG Phase II Trial.
Stephanie Lheureux,Ana Oaknin,Swati Garg,Jeffrey Bruce,Neesha C. Dhani,Ainhoa Madariaga,Luisa Bonilla,Yeh Chen Lee,Ilaria Colombo,Gita Bhat,Valerie Bowering,Justin White,Sarah Accardi,Susie Tan,Marsela Braunstein,Katherine Karakasis,Zhihui (Amy) Liu,Trevor J. Pugh,Amit M. Oza +18 more
TL;DR: This data indicates that continuation of treatment with or without chemotherapy for high grade serous ovarian cancer after initial treatment with PARP inhibitors for atypical ovarian cancer may be a viable strategy for these patients.
Journal ArticleDOI
Performance characteristics of screening strategies to identify Lynch syndrome in women with ovarian cancer
Soyoun Rachel Kim,Soyoun Rachel Kim,Alicia A. Tone,Raymond H. Kim,Raymond H. Kim,Raymond H. Kim,Matthew Cesari,Blaise A. Clarke,Lua Eiriksson,Tae L. Hart,Tae L. Hart,Melyssa Aronson,Spring Holter,Alice Lytwyn,Manjula Maganti,Leslie Oldfield,Steven Gallinger,Marcus Q. Bernardini,Marcus Q. Bernardini,Amit M. Oza,Bojana Djordjevic,Jordan Lerner-Ellis,Emily Van de Laar,Danielle Vicus,Danielle Vicus,Trevor J. Pugh,Trevor J. Pugh,Trevor J. Pugh,Aaron Pollett,Aaron Pollett,Sarah E. Ferguson,Sarah E. Ferguson,Sarah E. Ferguson +32 more
TL;DR: The performance characteristics of various strategies combining mismatch repair (MMR) immunohistochemistry, microsatellite instability testing (MSI), and family history for the detection of Lynch syndrome are compared.
Journal ArticleDOI
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
Elizabeth M. Swisher,Rebecca Kristeleit,Amit M. Oza,Anna V. Tinker,Isabelle Ray-Coquard,Ana Oaknin,Robert L. Coleman,Howard A. Burris,Carol Aghajanian,David M. O'Malley,Alexandra Leary,Stephen Welch,Diane Provencher,Geoffrey I. Shapiro,Lee-may Chen,Ronnie Shapira-Frommer,Scott H. Kaufmann,Sandra Goble,Lara Maloney,Tanya Kwan,Kevin K. Lin,Iain A. McNeish +21 more
TL;DR: In this article, the authors describe molecular and clinical characteristics of patients with high-grade recurrent ovarian carcinoma (HGOC) who had long-term responses to the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib.
Journal ArticleDOI
Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86)
Neesha C. Dhani,Hal W. Hirte,Lisa Wang,Julia V. Burnier,Angela Jain,Marcus O. Butler,Stephen Welch,Gini F. Fleming,Jean A. Hurteau,Koji Matsuo,Daniela Matei,Waldo Jimenez,Carolyn Johnston,Mihaela C. Cristea,Katia Tonkin,Prafull Ghatage,Stephanie Lheureux,Anjali Mehta,Judy Quintos,Qian Tan,Suzanne Kamel-Reid,Olga Ludkovski,Ming-Sound Tsao,John Wright,Amit M. Oza +24 more
TL;DR: Cabozantinib has activity in serous and endometrioid histology endometrial cancer and increased frequency of responses with somatic CTNNB1 mutation and concurrent KRAS and PTEN/PIK3CA mutations is observed.
Journal ArticleDOI
Wanna Get Away? Maintenance Treatments and Chemotherapy Holidays in Gynecologic Cancers.
TL;DR: Additional trials assessing maintenance strategies in ovarian and other gynecologic malignancies are needed, as an overall survival advantage remains unclear, and the use of these approaches thus remains controversial.